Want to see TSE:PHRX full AI Analyst Report?
PHRX Stock Chart & Stats
C$0.01
<C$0.01(100.00%)
At close: 4:00 PM EDT
C$0.01
<C$0.01(100.00%)
Day’s Range― - ―
52-Week Range<C$0.01 - C$0.03
Previous CloseN/A
Volume0.00
Average Volume (3M)29.64K
Market Cap
C$671.07K
Enterprise ValueC$2.44M
Total Cash (Recent Filing)C$28.36K
Total Debt (Recent Filing)C$1.71M
Price to Earnings (P/E)―
Beta-1.09
Next Earnings
Nov 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding134,214,390
10 Day Avg. Volume36,720
30 Day Avg. Volume29,642
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)-0.92
Price to Sales (P/S)0.00
P/FCF Ratio-18.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Cash BurnCash burn has improved materially from prior years, reducing the immediate pace of liquidity depletion. Although cash flow remains negative, a lower burn rate can extend funding runway and create more time for management to improve operations or secure financing.
Narrower Net LossThe substantially smaller TTM loss indicates progress from the company’s worst reported performance. While Pharmadrug remains unprofitable, reducing losses can lessen financing needs over time and provides evidence that the magnitude of deterioration is not continuing at the prior extreme.
Lower Historical Cash OutflowThe contrast between earlier annual cash burn and the current roughly $90K TTM outflow highlights meaningful cost or spending improvement. Sustaining this lower cash requirement would strengthen financial resilience, even though the business has not yet reached self-funding operations.
Bears Say
No Meaningful Revenue ScaleAn effectively nonexistent revenue base prevents the company from demonstrating product demand, operating scale, or a durable commercial engine. Negative gross profit further suggests current sales do not cover direct costs, leaving fixed expenses and future development dependent on outside funding.
Negative Shareholders’ EquityNegative equity signals that recorded liabilities exceed assets and materially weakens the balance sheet. This limits financial flexibility, reduces the buffer available to absorb further losses, and can make future capital raising or refinancing more important to continued operations.
Debt Exceeds Asset BaseDebt materially above the asset base indicates substantial leverage pressure relative to the resources supporting the business. Combined with ongoing losses and negative equity, this increases refinancing dependence and constrains the company’s ability to fund growth without external capital.
Pharmadrug News
PHRX FAQ
What was Pharmadrug’s price range in the past 12 months?
Pharmadrug lowest stock price was <C$0.01 and its highest was C$0.03 in the past 12 months.
What is Pharmadrug’s market cap?
Pharmadrug’s market cap is C$671.07K.
When is Pharmadrug’s upcoming earnings report date?
Pharmadrug’s upcoming earnings report date is Nov 30, 2026 which is in 37 days.
How were Pharmadrug’s earnings last quarter?
Pharmadrug released its earnings results on Aug 27, 2026. The company reported -C$0.002 earnings per share for the quarter.
Is Pharmadrug overvalued?
According to Wall Street analysts Pharmadrug’s price is currently Overvalued.
Does Pharmadrug pay dividends?
Pharmadrug does not currently pay dividends.
What is Pharmadrug’s EPS estimate?
Pharmadrug’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmadrug have?
Pharmadrug has 134,214,390 shares outstanding.
What happened to Pharmadrug’s price movement after its last earnings report?
Pharmadrug reported an EPS of -C$0.002 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Pharmadrug?
Currently, no hedge funds are holding shares in TSE:PHRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pharmadrug
Pharmadrug Inc., a Toronto-based specialty pharmaceutical firm, is dedicated to the research, development, and market introduction of controlled substances and natural therapeutics, such as psychedelics, cannabis, and other approved compounds derived from nature. The company also manages the import and supply of medical cannabis to pharmacies across Germany and the broader European Union. Additionally, it operates Super Smart, an entity focused on advancing the application of functional and psilocybin mushrooms, and engages in studies to reformulate established natural medicines. Pharmadrug maintains key research collaborations, including an agreement with the University of Michigan to explore the potential role of N, N-dimethyltryptamine (DMT) in various states of consciousness. It has also partnered with the Southwest Research Institute for the manufacturing of cepharanthine and entered into a clinical trial agreement with Johns Hopkins University to compare the acute and enduring psychological and neural effects of DMT against another potent active molecule. The company adopted its current name in October 2019, having previously operated as Aura Health Inc.